Risk thresholds for the frequency of cannabis use during pregnancy and adverse neonatal outcomes: protocol for a systematic review and dose-response meta-analysis

被引:0
作者
Robinson, Tessa [1 ]
Fischer, Benedikt [2 ,3 ,4 ,5 ,6 ]
Hautala, Rebecca [7 ]
Bertram, Mavoy [8 ]
Ali, Muhammad Usman [1 ,9 ]
Farrokhyar, Forough [1 ,10 ,11 ]
Jack, Susan [1 ,12 ,13 ]
Kapiriri, Lydia [1 ,14 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[2] Univ Fraser Valley, Res & Grad Studies, Abbotsford, BC, Canada
[3] Simon Fraser Univ, Fac Hlth Sci, Ctr Appl Res Mental Hlth & Addict, Vancouver, BC, Canada
[4] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[5] Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil
[6] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand
[7] McMaster Univ, Dept Midwifery, Midwifery Grad Program, Hamilton, ON, Canada
[8] York Univ, Fac Hlth, Sch Nursing, Toronto, ON, Canada
[9] McMaster Univ, McMaster Evidence Review & Synth Team, Hamilton, ON, Canada
[10] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[11] McMaster Univ, Fac Hlth Sci, Dept Global Hlth, Hamilton, ON, Canada
[12] McMaster Univ, Fac Hlth Sci, Sch Nursing, Hamilton, ON, Canada
[13] McMaster Univ, Offord Ctr Child Studies, Hamilton, ON, Canada
[14] McMaster Univ, Fac Social Sci, Dept Hlth Aging & Soc, Hamilton, ON, Canada
关键词
Cannabis; Pregnancy; Systematic review; Neonatal outcomes; Dose-response; MARIJUANA USE;
D O I
10.1186/s13643-024-02718-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cannabis use during pregnancy has been increasing and is associated with adverse neonatal outcomes, such as low birth weight (LBW) and preterm birth (PTB). It remains largely unknown whether the association between cannabis use in pregnancy and increased risk of adverse neonatal outcomes is impacted by the frequency of cannabis use and whether thresholds exist below which risk is not significantly increased. The objective of this systematic review is to assess whether the association between cannabis use during pregnancy and the risk of adverse neonatal outcomes is dependent on the frequency of use and whether risk thresholds exist. Methods For this systematic review and dose-response meta-analysis, the Embase, MEDLINE, PsycINFO, CINAHL, and Web of Science databases will be searched for relevant studies published in English from January 2010 onwards. Studies that include pregnant individuals with singleton pregnancies and evaluate the association between cannabis use in pregnancy and adverse neonatal outcomes using case-control, cohort, or cross-sectional designs will be considered for inclusion. Studies must include information on cannabis use frequency reported according to at least three of the pre-defined categories of no use, yearly (1-11 days per year), monthly (1-3 days per month), weekly (1-4 days per week), and daily/near daily use (5-7 days per week). At least one of the following neonatal outcomes must be reported, according to the frequency of cannabis use: LBW (< 1500 g), PTB (before 37 weeks gestation), neonatal intensive care unit (NICU) admission, and mortality. Studies will be included that report results as risk ratios (RR), odds ratios (OR), hazard ratios (HR), or that include the raw data to be able to calculate them. A two-stage dose-response meta-analysis will be conducted. The risk of bias of included studies will be assessed using the JBI tools for cohort, case-control, and cross-sectional studies. Certainty of the evidence will be reported according to the GRADE approach and the review will be reported according to PRISMA guidelines. Discussion The frequency of cannabis is one factor that may influence the relationship between cannabis use in pregnancy and adverse neonatal outcomes. This review will quantify this relationship by determining whether risk thresholds exist.
引用
收藏
页数:6
相关论文
共 34 条
  • [21] Callaghan R.C., Sanches M., Kish S.J., Quantity and frequency of cannabis use in relation to cannabis-use disorder and cannabis-related problems, Drug Alcohol Depend, 217, (2020)
  • [22] Dekkers O.M., Vandenbroucke J.P., Cevallos M., Renehan A.G., Altman D.G., Egger M., COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology, PLOS Med, 16, 2, (2019)
  • [23] Chandra S., Radwan M.M., Majumdar C.G., Church J.C., Freeman T.P., ElSohly M.A., New trends in cannabis potency in USA and Europe during the last decade (2008–2017), Eur Arch Psychiatry Clin Neurosci, 269, 1, pp. 5-15, (2019)
  • [24] Zhang J., Yu K.F., What’s the relative risk?: A method of correcting the odds ratio in cohort studies of common outcomes, JAMA, 280, 19, pp. 1690-1691, (1998)
  • [25] Orsini N., Larsson S., Salanti G., Dose-response meta-analysis, Systematic Reviews in Health Research: Meta-Analysis in Context, pp. 258-270, (2022)
  • [26] Liu Q., Cook N.R., Bergstrom A., Hsieh C.C., A two-stage hierarchical regression model for meta-analysis of epidemiologic nonlinear dose–response data, Comput Stat Data Anal, 53, 12, pp. 4157-4167, (2009)
  • [27] Discacciati A., Crippa A., Orsini N., Goodness of fit tools for dose–response meta-analysis of binary outcomes, Res Synth Methods, 8, 2, pp. 149-160, (2017)
  • [28] Viechtbauer W., Conducting meta-analyses in R with the metafor package, J Stat Softw, 36, 3, pp. 1-48, (2010)
  • [29] . R: A language and environment for statistical computing, Vienna, Austria: R Foundation for Statistical Computing, (2020)
  • [30] Higgins J.P.T., Thompson S.G., Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 11, pp. 1539-1558, (2002)